[1] Wilson S R, Burns P N. Microbubble-enhanced US in body imaging: what role[J].
Radiology, 2010,257(1):24
[2] Smeenge M, Mischi M, Laguna P, et al .Novel contrast-enhanced ultrasound imaging in
prostate cancer[J]. World J Urol, 2011,29(5):581
[3] Pitt W G, Husseini G A, Staples B J. Ultrasonic drug delivery-a general review[J].
Expert Opin Drug Deliv, 2004,1(1):37
[4] Feinstein S B, Ten C, Zwehl W, et al. Two-dimensional contrast echocardiography in
vitro development and quantitative analysis of echo contrast agents[J]. J Am Coll
Cardiol,1984,3(1):14
[5] 杜永峰,万明习,赵文明. 含蔗糖白蛋白包膜微泡超声造影剂制备研究[J]. 药学学报, 2001,36
(11):859
[6] Bauer A, Solbiati L, Weissman N. Ultrasound imaging with SonoVue: low mechanical
index real-time imaging[J]. Acad Radiol,2002,9(Suppl 2):S282
[7] Basude R, Duckworth J W, Wheatley M A. Influence of environmental conditions on a
new surfactant-based contrast agent: ST68[J]. Ultrasound Med Biol, 2000,26(4):621
[8] Shi W T, Forsberg F, Vaidyanathan P, et al. The influence of acoustic transmit
parameters on the destruction of contrast microbubbles in vitro[J]. Phys Med Biol, 2006,51
(16):4031
[9] Tabuchi Y, Takasaki I, Zhao Q L, et al. Genetic networks responsive to low-intensity
pulsed ultrasound in human lymphoma U937 cells[J]. Cancer Lett, 2008,270(2):286
[10] Cochran M C, Eisenbrey J, Ouma R O, et al. Doxorubicin and paclitaxel loaded
microbubbles for ultrasound triggered drug delivery[J]. Int J Pharm, 2011,414(1/2): 161
[11] Stride E P, Coussios C C. Cavitation and contrast: the use of bubbles in ultrasound
imaging and therapy[J]. Proc Inst Mech Eng H, 2010, 224(2): 171
[12] Li X H, Zhou P, Wang L H, et al. The targeted gene (KDRP-CD/TK) therapy of breast
cancer mediated by SonoVue and ultrasound irradiation in vitro[J]. Ultrasonics, 2012,52
(1):186
[13] Phillips L C, Klibanov A L, Wamhoff B R, et al. Targeted gene transfection from
microbubbles into vascular smooth muscle cells using focused, ultrasound-mediated delivery
[J]. Ultrasound Med Biol, 2010, 36(9):1470
[14] Shapiro G, Wong A W, Bez M, et al. Multiparameter evaluation of in vivo gene delivery
using ultrasound-guided, microbubble-enhanced sonoporation[J]. J Control Release, 2016,223
(223):157
[15] Xiang X, Tang Y, Leng Q, et al. Targeted gene delivery to the synovial pannus in
antigen-induced arthritis by ultrasound-targeted microbubble destruction in vivo[J].
Ultrasonics, 2016,65(65):304
[16] Jing H, Cheng W, Li S, et al. Novel cell-penetrating peptide-loaded nanobubbles
synergized with ultrasound irradiation enhance EGFR siRNA delivery for triple negative
breast cancer therapy[J]. Colloids Surf B Biointerfaces, 2016,146(146):387
[17] Schlegel P, Huditz R, Meinhardt E, et al. Locally targeted cardiac gene delivery by
AAV microbubble destruction in a large animal model[J]. Hum Gene Ther Methods, 2016,27
(2):71
[18] Uemura H, Sano F, Nomiya A, et al. Usefulness of perflubutane microbubble-enhanced
ultrasound in imaging and detection of prostate cancer: phase II multicenter clinical
trial[J]. World J Urol, 2013, 31(5):1123
[19] Klibanov A L. Microbubble contrast agents: targeted ultrasound imaging and
ultrasound-assisted drug-delivery applications[J].Invest Radiol, 2006,41(3):354
[20] Wang L, Li L, Guo Y, et al. Construction and in vitro/in vivo targeting of PSMA-
targeted nanoscale microbubbles in prostate cancer[J]. Prostate, 2013,73(11):1147
[21] Fan X, Wang L, Guo Y, et al. Ultrasonic nanobubbles carrying Anti-PSMA nanobody:
construction and application in prostate cancer-Targeted imaging[J]. PLoS One,2015,10
(6):e0127419
[22] Fan X, Guo Y, Wang L, et al. Diagnosis of prostate cancer using anti-PSMA aptamer
A10-3.2-oriented lipid nanobubbles[J]. Int J Nanomedicine, 2016,11:3939
[23] Tinkov S, Bekeredjian R, Winter G, et al. Microbubbles as ultrasound triggered drug
carriers[J]. J Pharm Sci, 2009,98(6):1935
[24] Taniyama Y, Tachibana K, Hiraoka K, et al. Local delivery of plasmid DNA into rat
carotid artery using ultrasound[J]. Circulation, 2002,105(10):1233
[25] Ter Haar G R. Ultrasonic contrast agents: safety considerations reviewed[J]. Eur J
Radiol, 2002,41(3):217
[26] Kang S T, Yeh C K. Ultrasound microbubble contrast agents for diagnostic and
therapeutic applications: current status and future design[J]. Chang Gung Med J, 2012,35
(2):125
[27] Eggen S, Fagerland S M, M?覬rch■, et al. Ultrasound-enhanced drug delivery in
prostate cancer xenografts by nanoparticles stabilizing microbubbles[J]. J Control
Release, 2014,187:39
[28] Fan X, Wang L, Guo Y, et al. Inhibition of prostate cancer growth using doxorubicin
assisted by ultrasound-targeted nanobubble destruction[J]. Int J Nanomedicine, 2016,11:3585
[29] Wang Y, Bai W K, Shen E, et al. Sonoporation by low-frequency and low-power
ultrasound enhances chemotherapeutic efficacy in prostate cancer cells in vitro[J]. Oncol
Lett, 2013,6(2):495
[30] Wei C, Bai W K, Wang Y, et al. Combined treatment of PC-3 cells with ultrasound and
microbubbles suppresses invasion and migration[J]. Oncol Lett, 2014,8(3):1372
[1]魏强,齐灿,罗飞,等.转移性去势抵抗性前列腺癌患者多西他赛化疗的预后分析[J].天津医科大学学报,2013,19(05):390.
[2]杨帮东,姜行康,齐 灿,等.尿液中PCA3评分对前列腺癌早期诊断的临床意义[J].天津医科大学学报,2013,19(06):487.
YANG Bang-dong,JIANG Xing-kang,QI Can,et al.Clinical significance of urinary PCA3 score to diagnose prostate cancer[J].Journal of Tianjin Medical University,2013,19(02):487.
[3]刘利维,刘春雨. MicroRNAs 与前列腺癌的表观遗传学研究进展[J].天津医科大学学报,2014,20(01):74.
[4]杨 虹,田凤石.颈动脉内中膜厚度与H型高血压及相关因素的分析[J].天津医科大学学报,2014,20(02):137.
YANG Hong,TIAN Feng-Shi.Analysis of carotid intima-media thickness , H type of hypertension and related factors[J].Journal of Tianjin Medical University,2014,20(02):137.
[5]单 琨,李常颖.超声和CT检查对于肾上腺区占位性病变的诊断价值对比分析[J].天津医科大学学报,2014,20(04):306.
SHAN Kun,LI Chang-ying.Comparative analysis on ultrasound and CT examination of adrenal area space-occupying lesions[J].Journal of Tianjin Medical University,2014,20(02):306.
[6]王 超,余泉峰,徐 勇,等.经直肠超声造影诊断前列腺癌的临床分析[J].天津医科大学学报,2014,20(05):375.
WANG Chao,YU Quan-feng,XU Yong,et al.Clinical analysis of contrast-enhanced transrectal ultrasonography for the diagnosis of prostate cancer[J].Journal of Tianjin Medical University,2014,20(02):375.
[7]张晓会,张志宏,徐 勇,等.合并症对局限性或局部晚期前列腺癌患者早期生存的影响[J].天津医科大学学报,2014,20(05):379.
ZHANG Xiao-hui,ZHANG Zhi-hong,XU Yong,et al. Influence of complications on early survival of patients with localized or locally advanced prostate cancer[J].Journal of Tianjin Medical University,2014,20(02):379.
[8]张 岱,忻晓洁,张 晟,等.常规超声与超声造影对小肾癌诊断的对比研究[J].天津医科大学学报,2015,21(03):226.
[9]盛 镔,张 蒙,马鹏德,等.核糖体蛋白L37在前列腺癌中的表达及临床意义[J].天津医科大学学报,2015,21(05):401.
SHENG Bin,ZHANG Meng,MA Peng-de,et al.Expression of ribosomal protein L37 in prostate cancer and its clinical significance[J].Journal of Tianjin Medical University,2015,21(02):401.
[10]管明秀,周云丽,王 萌,等.TuM2-PK,tPSA,fPSA/tPSA和PSAD对PSA灰区前列腺癌诊断价值的比较[J].天津医科大学学报,2016,22(02):140.
GUAN Ming-xiu,ZHOU Yun-li,WANG-Meng,et al.Diagnostic implication of TuM2-PK, tPSA, fPSA/tPSA ratio and PSAD for prostate cancer in PSA gray area[J].Journal of Tianjin Medical University,2016,22(02):140.